Lakefront Biotherapeutics | GLPG - Interest Expense On Debt


Lakefront Biotherapeutics reported EUR1.72M in Interest Expense on Debt for its fiscal quarter ending in September of 2025.





Interest Expense On Debt Change Date
argenx SE USD 1000K 172K Mar/2026
AstraZeneca USD 340M 144M Jun/2026
Biogen USD 72.6M 12.6M Jun/2025
Genmab DKK 139M 129M Jun/2026
Gilead Sciences USD 247M 7M Jun/2026
GlaxoSmithKline GBP 121M 46M Jun/2026
GRIFOLS EUR 141.43M 61.28M Jun/2025
Hikma Pharmaceutical USD 67M 47M Dec/2025
Incyte USD 582K 13K Jun/2026
Merck EUR 137M 33M Jun/2026
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Novartis USD 462M 119M Jun/2026
Roche Holding CHF 304M 7.5M Jun/2025
Sanofi EUR 287M 109M Jun/2026
UCB EUR 49M 29M Dec/2025
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025